Taysha reports 100% milestone response in Phase 1/2 REVEAL Part A for TSHA-102; 165 additional functional gains

Taysha Gene Therapies, Inc.

All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.
22 developmental milestones gained across domains of communication, fine motor, gross motor.
Supplemental analysis: 165 additional skills/improvements across all 10 patients from structured scales (MSEL-A, R-MBA, ORCA).
Data presented at 54th CNS Annual Meeting; reinforces broad, multi-domain impact on activities of daily living.
Study evaluates high dose (1x10^15 vg) and low dose (5.7x10^14 vg) in females aged 6-21 years with Rett syndrome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.